The unique characteristics of COVID-19 coagulopathy

Area of Science:

• Hematology
• Infectious Diseases
• Critical Care Medicine

Background:

• Thrombotic complications and coagulopathy are common in COVID-19 patients.
• COVID-19-associated coagulopathy (CAC) exhibits distinct laboratory and clinical features compared to other coagulopathies.
• Distinguishing CAC from sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation (DIC) is clinically important.

Purpose of the Study:

• To delineate the unique characteristics of COVID-19-associated coagulopathy (CAC).
• To compare and contrast CAC with other major coagulopathies, including SIC and DIC.
• To highlight the distinct thrombotic tendencies and laboratory findings in CAC.

Main Methods:

• Review and synthesis of existing literature on COVID-19 coagulopathy.
• Comparative analysis of clinical and laboratory data from CAC, SIC, DIC, and related syndromes.
• Identification of key differentiating markers and features.

Main Results:

• CAC typically shows elevated D-dimer and fibrinogen with initially normal prothrombin time and platelet counts.
• Venous and arterial thrombosis are more prevalent in CAC than in SIC/DIC.
• CAC shares some features with hemophagocytic syndrome, antiphospholipid syndrome, and thrombotic microangiopathy.

Conclusions:

• COVID-19-associated coagulopathy is a distinct entity with specific pathophysiological mechanisms.
• Recognizing the unique profile of CAC aids in appropriate diagnosis and management.
• Further research is warranted to fully elucidate the complexities of CAC and its treatment.